Abbott Laboratories (ABT)
Pretax margin
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 7,013,000 | 6,778,000 | 6,509,000 | 6,538,000 | 6,664,000 | 6,189,000 | 6,276,000 | 6,992,000 | 8,306,000 | 9,313,000 | 10,048,000 | 9,044,000 | 8,211,000 | 8,272,000 | 7,200,000 | 6,378,000 | 4,968,000 | 3,820,000 | 3,502,000 | 4,078,000 |
| Revenue (ttm) | US$ in thousands | 41,950,000 | 41,217,000 | 40,725,000 | 40,326,000 | 40,109,000 | 39,959,000 | 40,226,000 | 41,505,000 | 43,653,000 | 45,030,000 | 45,548,000 | 44,514,000 | 43,075,000 | 42,308,000 | 40,233,000 | 37,338,000 | 34,608,000 | 32,221,000 | 31,444,000 | 32,095,000 |
| Pretax margin | 16.72% | 16.44% | 15.98% | 16.21% | 16.61% | 15.49% | 15.60% | 16.85% | 19.03% | 20.68% | 22.06% | 20.32% | 19.06% | 19.55% | 17.90% | 17.08% | 14.36% | 11.86% | 11.14% | 12.71% |
December 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $7,013,000K ÷ $41,950,000K
= 16.72%
Abbott Laboratories' pretax margin has experienced fluctuations over the quarters provided in the data. The pretax margin indicates the company's profitability before accounting for tax expenses. From March 31, 2020, to June 30, 2022, there was a steady increase in the pretax margin, reaching a peak of 22.06%. This upward trend suggests improving operational efficiency and cost management during this period.
However, in the subsequent quarters from September 30, 2022, to December 31, 2024, the pretax margin experienced some level of decline, fluctuating within a range from 15.49% to 16.72%. This may indicate increased operating costs, changes in revenue composition, or other factors influencing profitability during this time frame.
Overall, Abbott Laboratories has shown a generally positive trend in its pretax margin performance, with notable peaks in profitability followed by periods of slight decline. It will be important for stakeholders and investors to monitor future financial results to understand the factors driving these fluctuations in pretax margin and assess the company's overall financial health and performance.
Peer comparison
Dec 31, 2024